Combined Industry view on Eudravigilance Developments and access

- EFPIA, AESGP, EuropaBIO, EGA
- Delay in centralisation
  - MS should be encouraged to centralise earlier when they assess EV as functional
- Submission of non serious data.
  - What are the requirements before centralisation in the individual countries?
  - How to solve with linelistings in the PSURs
- Retrieve reports from literature and direct reporting to MS
  - requirements, format and possibilities
- Signal detection
  - Should the MAH copy the actions of the EMA on the data in EV?
- Access policy for CAP by end of 2011.
  - What are MA holder obligations
  - How many industry access points
  - License partners / generics
  - Non serious reports